financial results

Kane Biotech Announces Third Quarter 2025 Financial Results

1 week ago talkbio0Tagged Clearance, distributor network, financial results, gross profit, Kane Biotech, net loss, Revenue, revyve, third quarter 2025, United States, United States Food and Drug Administration, wound care

Kane Biotech; third quarter 2025; financial results; revenue; gross profit; net loss; revyve; wound care; FDA 510(k) clearance; U.S. distributor network

Rakovina Therapeutics Announces Q3 2025 Financial Results and Corporate Update

1 week ago talkbio0Tagged AI-powered, ATR Inhibitor, Clinical Nurse Specialists, Conferences, corporate milestones, development expenses, Ditiocarb, Drug Discovery, Eligibility Determination, financial results, Investments, NanoPalm joint-venture, net loss, Penetration, Q3, Rakovina, research

Rakovina Therapeutics; Q3 2025; financial results; net loss; research and development expenses; AI-powered drug discovery; ATR inhibitor; CNS penetration; corporate milestones; NanoPalm joint-venture; investment conference; DTC eligibility

BridgeBio Oncology Therapeutics: Recent News Overview (November 2025)

2 weeks ago talkbio0Tagged AACR-NCI-EORTC, BridgeBio Oncology Therapeutics, clinical-stage biopharma, de-SPAC transaction, financial results, financing characteristics, Helix Acquisition Corp II, PI3Kδ, Piperine Extract (Standardized), ras Oncogene, third quarter 2025

BridgeBio Oncology Therapeutics; Helix Acquisition Corp II; de-SPAC transaction; PIPE financing; RAS and PI3Kα; clinical-stage biopharma; AACR-NCI-EORTC Conference; third quarter 2025 financial results

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

4 weeks ago talkbio0Tagged Capitalization, clinical-stage biopharma, development aspects, exophthalmos producing substance, financial results, Impaired, Market, net loss, Nkarta, Operating expenses, Q3, research

Nkarta; Q3 2025 financial results; net loss; operating expenses; EPS; research and development; impairment; market capitalization; clinical-stage biopharma; corporate highlights

Puma Biotechnology Reports Third Quarter 2025 Financial Results

1 month ago talkbio0Tagged beat, Clinical Trials, EPS, exophthalmos producing substance, financial results, Neoplasms, Nerlynx sales, net income, Puma Biotechnology, Q3, Revenue Decline, revenue guidance

Puma Biotechnology; Q3 2025; financial results; EPS beat; revenue decline; Nerlynx sales; net income; oncology; clinical trials; revenue guidance

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

1 month ago talkbio0Tagged BEACON-IPF, cash reserves, Clinical Trials, development expenses, financial results, net loss, oncology program, Oxford Finance, Pliant Therapeutics, PLN-101095, Q3, research

Pliant Therapeutics; Q3 2025 financial results; PLN-101095; oncology program; BEACON-IPF trial; net loss; research and development expenses; cash reserves; Oxford Finance loan repayment

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

1 month ago talkbio0Tagged B-Cell Lymphomas, Business Update, Cancer Therapeutic Procedure, cash position, Clinical Trials, financial results, Immunome, net loss, pipeline update, Q3, RINGSIDE trial, therapeutic autologous dendritic cells, varegacestat

Immunome; Q3 2025; financial results; business update; pipeline update; cancer therapies; RINGSIDE trial; varegacestat; IM-1021; B-cell lymphoma; clinical trials; ADC; net loss; cash position

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

1 month ago talkbio0Tagged Autoimmune Diseases, cash runway, CIDP CAPTIVATE trial, claseprubart, Dianthus Therapeutics, DNTH212, expense, financial results, MaGic trial, Q3

Dianthus Therapeutics; Q3 2025 financial results; claseprubart; DNTH212; autoimmune disease; MaGic trial; CIDP CAPTIVATE trial; R&D expenses; net loss; $525M cash runway

Gilead Cell Therapy Sales Drop 11% in Q3 2025, HIV Franchise Drives Growth

1 month ago talkbio0Tagged Biktarvy, cell therapy sales, financial results, Gilead Sciences, HIV franchise, Livdelzi, Q3, Tecartus, Trodelvy, Veklury, Yescarta, Yeztugo

Gilead Sciences; cell therapy sales; Q3 2025 financial results; HIV franchise; Yescarta; Tecartus; Biktarvy; Yeztugo; Livdelzi; Trodelvy; Veklury

Sarepta Pursues Efficiency Measures Amid $1 Billion Debt Due in 2027

4 months ago talkbio0Tagged 2025, debt, decline, Efficiency, ELEVIDYS, Financial cost, financial results, Financial savings, Measures, Muscular Dystrophy, Duchenne, restructuring, United States Food and Drug Administration

Sarepta Therapeutics; debt 2027; efficiency measures; ELEVIDYS; cost savings; restructuring; financial results 2025; FDA; Duchenne muscular dystrophy; stock decline